Roots Analysis has done a detailed study on Exosome Therapeutics Market, 2022-2040, covering key aspects of the industry and identifying future growth opportunities

Key Market Insights

§  Close to 60 players, worldwide, have taken initiatives to develop exosome therapeutics; the market is characterized by the presence of start-ups and small companies

§  The current pipeline features more than 120 exosome therapeutics that are being evaluated across different phases of development; most of these are designed for intravenous administration

§  3,000+ patients have been recruited / enrolled in clinical trials evaluating exosome related therapies and biomarkers across different geographies

§  More than 530 grants have been awarded for the ongoing R&D efforts for exosome therapeutics; University of California has been awarded the maximum grant amount of USD 21 million

§  A variety of investors, having realized the benefits and future opportunities in this field, have invested more than USD 570 million across more than 30 instances, since 2017

§  The rising interest of stakeholders in exosome therapeutics is also reflected by the increasing number of partnerships established by various industry and non-industry players

§  Stakeholders have participated in various global events to discuss the research outcomes, and affiliated challenges as well as opportunities existing in this domain

§  At present, more than 30 start-ups are driving innovation in this domain; a variety of R&D initiatives have been undertaken by these players over the last few years for the development of exosome therapeutics

§  Lack of efficacy, COVID-19 pandemic, limited patient enrollment, and scarce funding are among the key reasons that have led to the discontinuation of studies sponsored by various industry and non-industry players

§  With the rising demand for therapeutic advances in drug safety, the market of exosome therapeutics is expected to grow at an annualized rate of 41% between 2029-2040

§  The projected market opportunity is likely to be well distributed across different routes of administration, types of formulations and key geographical regions

Table of Contents

1.         PREFACE

1.1.      Scope of the Report

1.2.      Market Segmentation

1.3.      Research Methodology

1.4.      Key Questions Answered

1.5.      Chapter Outlines

2.         EXECUTIVE SUMMARY

3.         INTRODUCTION

3.1.      Overview of Exosomes

3.1.1.   Types of Extracellular Vesicles

3.1.1.   Potential Sources of Exosomes

3.2.      Exosome Biogenesis

3.2.1.   Exosome Formation and Development Process

3.2.2.   Secretion of Exosomes

3.3.      Applications of Exosomes

3.4.      Mechanism of Exosome Therapy

3.4.1.   Exosome Drug Therapy

3.4.2.   Exosome RNAi Therapy

3.4.3.   Exosome Immunotherapy

3.5.      Advantages of Exosome Therapies

3.6.      Risks and Future Perspectives Associated with Exosome Therapeutics

4.         EXOSOME THERAPEUTICS: MARKET LANDSCAPE

4.1.      Analysis Methodology and Key Parameters

4.2.      Exosome Therapeutics Market Landscape

4.2.1.   Analysis by Phase of Development

4.2.2.   Analysis by Technology Platform

4.2.3.   Analysis by Type of Payload

4.2.4.   Analysis by Derived Source

4.2.5.   Analysis by Target Disease Indication(s)

4.2.6.   Analysis by Therapeutic Area

4.2.7.   Analysis by Phase of Development and Therapeutic Area

4.2.8.   Analysis by Therapeutic Area and Route of Administration

4.2.9.   Analysis by Route of Administration

4.2.10  Analysis by Area of Application

4.2.11.             Analysis by Type of Therapy

4.2.12.             Analysis by Dosing Frequency

4.2.13.             Analysis by Type of Therapy (By Method of Composition)

4.2.14.             Analysis by Line of Treatment

4.3.      Exosome Therapeutics Developers

4.3.1.   Analysis by Year of Establishment

4.3.2.   Analysis by Company Size

4.3.3.   Analysis by Location of Headquarters

4.3.4.   Most Active Players: Analysis by Number of Therapeutics

5.         EXOSOME THERAPEUTICS DEVELOPERS: COMPANY PROFILES

5.1.      Coya Therapeutics

5.1.1.   Company Overview

5.1.2.   Product Portfolio

5.1.3.   Recent Developments and Future Outlook

5.2.      Codiak BioSciences

5.3.1.   Company Overview

5.3.2.   Product Portfolio

5.3.3.   Clinical Trial Information

5.3.4.   Recent Developments and Future Outlook

5.4.      Evox Therapeutics

5.4.1.   Company Overview

5.4.2.   Product Portfolio

5.4.3.   Recent Developments and Future Outlook

5.5.      Curexsys

5.5.1.   Company Overview

5.5.2.   Product Portfolio

5.5.3.   Recent Developments and Future Outlook

5.6.      EV Therapeutics

5.6.1.   Company Overview

5.6.2.   Product Portfolio

5.6.3.   Recent Developments and Future Outlook

5.7.      SHIFTBIO

5.7.1.   Company Overview

5.7.2.   Product Portfolio

5.7.3.   Recent Developments and Future Outlook

6.         EXOSOME THERAPEUTICS: DRUG PROFILES

6.1.      AEGLE Therapeutics

6.1.1.   Company Overview

6.1.2.   AGLE-102: Product Portfolio

6.1.2.1. AGLE-102: Clinical Trial Information

6.1.3.   Recent Developments and Future Outlook

6.2.      AVEM Healthcare

6.2.1.   Company Overview

6.2.2.   Ardoxso: Product Portfolio

6.2.2.1. Ardoxso: Clinical Trial Information

6.2.3.   Recent Developments and Future Outlook

6.3.      Cellular Biomedicine Group

6.3.1.   Company Overview

6.3.2.   Financial Information

6.3.3.   haMPC-Exos: Product Portfolio

6.3.3.1.            haMPC-Exos: Clinical Trial Information

6.3.4.   hMSC-Exos: Product Portfolio

6.3.4.1.            hMSC-Exos: Clinical Trial Information

6.3.5.   Undisclosed Drug 1: Product Portfolio

6.3.5.1.            Undisclosed Drug 1: Clinical Trial Information

6.3.6.   Recent Developments and Future Outlook

6.4.      OBCTCD24

6.4.1.   Company Overview

6.4.2.   CovenD24: Product Portfolio

6.4.2.1.            CovenD24: Clinical Trial Information

6.4.3.   Recent Developments and Future Outlook

6.5.      ReNeuron

6.5.1.   Company Overview

6.5.2.   Financial Information

6.5.3.   Undisclosed Drug 1: Product Portfolio

6.5.3.1.            Undisclosed Drug 1: Clinical Trial Information

6.5.4.   Recent Developments and Future Outlook

6.6.      Stem Cell Medicine

6.6.1.   Company Overview

6.6.2.   Undisclosed Drug 1: Product Portfolio

6.6.3.   Recent Developments and Future Outlook

7.         CLINICAL TRIAL ANALYSIS

7.1.      Analysis Methodology and Key Parameters

7.2.      Exosome Therapeutics: List of Clinical Trials

7.2.1.   Analysis by Trial Status

7.2.2.   Analysis by Trial Registration Year

7.2.3.   Analysis by Sponsor / Collaborator

7.2.4.   Analysis by Trial Registration Year and Type of Study

7.2.5.   Analysis by Trial Registration Year and Trial Status

7.2.6.   Analysis by Annual Number of Patients Enrolled

7.2.7.   Analysis by Study Design

7.2.8.   Analysis by Age Category

7.2.9.   Analysis by Phase of Development and Trial Status

7.2.10.             Analysis by Phase of Development and Patients Enrolled

7.2.11.             Most Active Industry Players: Analysis by Number of Registered Trials

7.2.12.             Most Active Non-Industry Players: Analysis by Number of Registered Trials

7.2.13. Analysis by Trial Location

7.2.14.             Analysis by Trial Status and Geography

7.2.15.             Analysis by Trial Status, Patients Enrolled and Geography

8.         ACADEMIC GRANT ANALYSIS

8.1.      Analysis Methodology and Key Parameters

8.2.      Exosome Therapeutics: List of Academic Grants

8.3.      Analysis by Year of Grants Awarded

8.4.      Analysis by Amount Awarded per Year

8.5.      Analysis by Type of Funding Institute Center

8.6.      Analysis by Support Period

8.7.      Analysis by Purpose of Grant

8.8.      Word Cloud Analysis: Emerging Focus Area

8.9.      Analysis by Grant Activity Code

8.10.    Analysis by Location of Recipient Organizations

8.11.    Popular Recipient Organizations: Analysis by Number of Grants

8.12.    Popular Recipient Organizations: Analysis by Amount Awarded

8.13.    Analysis by Type of Recipient Organization

8.14.    Analysis by Study Section

8.15.    Analysis by Type of Grant Application

8.16.    Analysis by Funding Institute Center and Support Year

9.         GLOBAL EVENT ANALYSIS

9.1.      Chapter Overview

9.2.      Scope and Methodology

9.3.      List of Global Events Related to Exosomes

9.3.1.   Analysis by Year of Event

9.3.2.   Analysis by Event Platform

9.3.3.   Analysis by Type of Event

9.3.4.  Analysis by Region

9.3.5.   Most Active Organizers: Analysis by Number of Events

9.3.6.   Most Active Speakers: Analysis by Number of Events

9.3.7.   Most Active Industry Participants: Analysis by Number of Events

9.3.8.    Most Active Non-Industry Participants: Analysis by Number of Events

9.3.9.   Analysis by Designation of Participant

9.3.10. Analysis by Affiliated Department of Participant

9.3.11. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area

10.       PARTNERSHIPS AND COLLABORATIONS

10.1.    Chapter Overview

10.2.    Partnership Models

10.3.    Exosome Therapeutics: List of Partnerships and Collaborations

10.3.1.             Analysis by Year of Partnership

10.3.2.             Analysis by Type of Partnership

10.3.3.             Analysis by Year and Type of Partnership

10.3.4. Analysis by Company and Type of Partnership

10.3.5. Analysis by Type of Technology Platform

10.3.6.             Analysis by Type of Partner

10.3.7. Most Active Players: Analysis by Number of Partnerships

10.3.8.             Word Cloud Analysis: Emerging Focus Areas

10.3.9. Analysis by Target Disease Indication(s)

10.3.10.Analysis by Therapeutic Area

10.3.11.Analysis by Therapeutic Area and Type of Partnership

10.3.12. Regional Distribution of Partnerships

10.3.13. Distribution by Geography

11.       FUNDING AND INVESTMENT ANALYSIS

11.1.    Analysis Methodology and Key Parameters

11.2.    Type of Funding

11.3.    Exosome Therapeutics: List of Funding Instances

11.4.    Analysis by Year of Funding

11.5.    Analysis by Amount Invested

11.6.    Analysis by Type of Funding

11.7.    Analysis by Type of Funding and Amount Invested

11.8.    Analysis by Purpose of Funding

11.9.    Analysis by Target Disease Indication(s)

11.10. Analysis by Therapeutic Area

11.11. Most Active Players: Analysis by Number of Funding Instances

11.12. Most Active Players: Analysis by Amount Raised

11.13. Active Investors: Analysis by Number of Funding Instances

11.14. Distribution by Geography

11.15. Summary of Funding Activity

12.       START-UP HEALTH INDEXING

12.1.    Analysis Methodology and Key Parameters

12.2.    Analysis by Pipeline Strength

12.3.    Analysis by Pipeline Maturity

12.4.    Analysis by Indication Diversity

12.5.    Analysis by Number of Partnerships

12.6.    Analysis by Financial Support

12.7.    Start-up Health Indexing: Roots Analysis Perspective

12.8.    Most Active Start-ups

13.       CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING SERVICE PROVIDERS

13.1.    Chapter Overview

13.2.    Exosome Development and Manufacturing Service Providers Landscape

13.2.1. Analysis by Year of Establishment

13.2.2. Analysis by Company Size

13.2.3. Analysis by Location of Headquarters

13.2.4. Analysis by Location of Headquarters and Company Size

13.3.    Analysis by Type of Service(s) Offered

13.3.1. Analysis by Method of Isolation

13.3.2. Analysis by Method of Purification

13.3.3. Analysis by Method of Characterization

13.3.4. Analysis by Method of Exosome Manufacturing      

13.3.5. Analysis by Scale of Operation

13.3.6. Analysis by Scalability

14.       DRUG FAILURE ANALYSIS

14.1.    Methodology and Key Parameters

14.2.    Exosome Therapeutics: List of Failed Drug Candidates

14.2.1. Analysis by Trial Start and Discontinuation Year

14.2.2.             Analysis by Trial Status of Discontinuation

14.2.3.             Analysis by Target Disease Indication(s)

14.2.4.             Analysis by Route of Administration

14.2.5.             Analysis by Type of Sponsor

14.2.6.             Analysis by Reasons for Drug Failure

14.2.7.             Word Cloud Analysis: Emerging Focus Area

15.       MARKET SIZING AND OPPORTUNITY ANALYSIS

15.1.    Forecast Methodology and Key Assumptions

15.2.    Global Exosome Therapeutics Market, 2029-2040

15.2.1.             Exosome Therapeutics Market for Allogeneic Therapy, 2029-2040 (USD Million)

15.2.2.             Exosome Therapeutics Market for Autologous Therapy, 2029-2040 (USD Million)

15.2.3. Exosome Therapeutics Market for Degenerative Meniscal Injury, 2031-2040 (USD Million)

15.2.4. Exosome Therapeutics Market for Dystrophic Epidermolysis Bullosa, 2030-2040 (USD Million)

15.2.5. Exosome Therapeutics Market for Fistula Perianal, 2029-2040 (USD Million)

15.2.6. Exosome Therapeutics Market for Retinitis Pigmentosa, 2029-2040 (USD Million)

15.2.7. Exosome Therapeutics Market for Dermatological Disorders, 2030-2040 (USD Million)

15.2.8. Exosome Therapeutics Market for Muscoskeletal Disorders, 2031-2040 (USD Million)

15.2.9. Exosome Therapeutics Market for Ophthalmic Disorders, 2029-2040 (USD Million)

15.2.10. Exosome Therapeutics Market for Rectal Disorders, 2029-2040 (USD Million)

15.2.11. Fistula Tract Exosome Therapeutics Market, 2029-2040 (USD Million)

15.2.12. Intra-articular Exosome Therapeutics Market, 2031-2040 (USD Million)

15.2.13. Intra-ocular Exosome Therapeutics Market, 2029-2040 (USD Million)

15.2.14.  Exosome Therapeutics Market Geographical Distribution, 2029-2040 (USD Million)

15.2.15. Erciyes University’s Drug: Sales Forecast, 2029-2040 (USD Million)

15.2.16. Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, 2031-2040 (USD Million)

15.2.17. AGLE-102: Sales Forecast, 2030-2040 (USD Million)

15.2.18. Trehan University of Medical Sciences’ Drug: Sales Forecast, 2029-2040 (USD Million)

15.2.19. ReNeuron’ Drug: Sales Forecast, 2029-2040 (USD Million)

16.       EXECUTIVE INSIGHTS

16.1.    Capricor Therapeutics

16.1.1.             Company Snapshot

16.1.2.             Interview Transcript: Xavier Avat, Chief Business Officer

16.2.    Exogenus Therapeutics

16.2.1.             Company Snapshot

16.2.2.             Interview Transcript: Patricia C. Freire, R&D and Innovation Manager

16.3.    ILIAS Biologics

16.3.1.             Company Snapshot

16.3.2.             Interview Transcript: Soonho Song, Chief Business Officer

17.       APPENDIX 1: TABULATED DATA

18.       APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/exosome-therapeutics-market.html

You may also be interested in the following titles:

You may also like to learn what our experts are sharing in Roots educational series:

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com